Patents by Inventor Jianghuai Xu

Jianghuai Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LAG-3 AND PD-1/LAG-3-ANTIBODIES
    Publication number: 20240166745
    Abstract: The present disclosure relates to antibodies that bind to and agonize human LAG-3, and to bispecific antibodies that bind to and agonize each of human PD-1 and human LAG-3.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 23, 2024
    Inventors: Yaqiong LIN, Marta Antonina WITEK, Jianghuai XU
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
    Publication number: 20240082414
    Abstract: The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
    Type: Application
    Filed: May 5, 2023
    Publication date: March 14, 2024
    Inventors: Grace Chao, Joshua R Clayton, Jordan Scott Crampton, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Kristin Paige Newburn, Scott Charles Potter, Bharathi Ramamurthy, David John Stokell, Jacqueline M. Wurst, Jianghuai Xu
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES
    Publication number: 20230192837
    Abstract: The present disclosure relates to antibodies that specifically bind soluble and membrane forms of human TNF?, compositions comprising such TNF? antibodies, and methods of using such TNF? antibodies and compositions.
    Type: Application
    Filed: November 10, 2022
    Publication date: June 22, 2023
    Inventors: Grace Chao, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Bharathi Ramamurthy, Jianghuai Xu
  • Engineered Antibody Compounds and Conjuates Thereof
    Publication number: 20200155702
    Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy.
    Type: Application
    Filed: June 14, 2018
    Publication date: May 21, 2020
    Inventors: Michael James Bacica, Yiqing Feng, Donmienne Doen Mun Leung, Matthew D. Linnik, Adam Robert Mezo, James Thomas Parker, Purva Vivek Trivedi, Francisco Alcides Valenzuela, Jianghuai Xu
  • VEGFA/Ang2 Compounds
    Patent number: 9932397
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: April 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Ying Tang, Peter Edward Vaillancourt, Jianghuai Xu
  • Ang2 antibodies
    Patent number: 9695241
    Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jianghuai Xu
  • VEGFR2/Ang2 Compounds
    Publication number: 20170121411
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventors: Donmienne Doen Mun LEUNG, Ling LIU, Jirong LU, Ying TANG, Jianghuai XU
  • VEGFR2/Ang2 compounds
    Patent number: 9580499
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: February 28, 2017
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Ling Liu, Jirong Lu, Ying Tang, Jianghuai Xu
  • VEGFA/Ang2 Compounds
    Publication number: 20160215045
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Application
    Filed: January 25, 2016
    Publication date: July 28, 2016
    Inventors: Donmienne Doen Mun Leung, Ying Tang, Peter Edward Vaillancourt, Jianghuai Xu
  • Ang2 Antibodies
    Publication number: 20150329627
    Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Application
    Filed: May 12, 2015
    Publication date: November 19, 2015
    Inventors: Donmienne Doen Mun Leung, Jianghuai Xu
  • VEGFR2/Ang2 Compounds
    Publication number: 20150329626
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Application
    Filed: May 12, 2015
    Publication date: November 19, 2015
    Inventors: Donmienne Doen Mun Leung, Ling Liu, Jirong Lu, Ying Tang, Jianghuai Xu